Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ) announced that its CEO, Bruce Steel, will present at the H.C. Wainwright Virtual BioConnect Conference on January 10, 2022, at 7:00 am EST. The presentation will cover key topics, including itolizumab’s mechanism of action and topline data from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD). Regulatory feedback relevant to a pivotal aGVHD study and the EQUALISE study in systemic lupus erythematosus will also be discussed. A webcast will be available on the company’s website for 90 days.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that Bruce Steel, Equillium’s chief executive officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on January 10, 2022, at 7:00 am EST.

The presentation will provide a high-level overview of itolizumab’s mechanism of action followed by topline data from the company’s Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD), regulatory feedback leading directly to a pivotal study in aGVHD, and the EQUALISE study in systemic lupus erythematosus and lupus nephritis. Members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

A webcast of the presentation will be available under the “Investors” section of the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005418/en/

Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

ir@equilliumbio.com



Media Contacts

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

Source: Equillium, Inc.

FAQ

When will Equillium present at the H.C. Wainwright Virtual BioConnect Conference?

Equillium will present at the H.C. Wainwright Virtual BioConnect Conference on January 10, 2022, at 7:00 am EST.

What will Equillium discuss in their conference presentation?

Equillium will discuss itolizumab’s mechanism of action, topline data from the Phase 1b EQUATE study in aGVHD, and regulatory feedback on upcoming studies.

Where can I watch Equillium's conference presentation?

The presentation will be available on Equillium's website under the 'Investors' section for 90 days.

What studies related to itolizumab will Equillium cover during the conference?

Equillium will cover topline data from the EQUATE study in aGVHD and the EQUALISE study in systemic lupus erythematosus.

Who is the CEO of Equillium?

The CEO of Equillium is Bruce Steel.